Cellectricon AB, a Swedish biotech company, successfully provides
groundbreaking products to the pharmaceutical and biotechnology
industries. The company utilizes state-of-the-art interfaces to
biological systems by employing novel microfluidic technologies.
This enables completely new types of assays and devices with
superior performance characteristics and robustness. Cellectricon's
products address critical bottlenecks in the drug discovery process
and have been adopted by top-reference customers, including nine of
the top ten pharmaceutical companies.
n 2007, the company increased its annual revenue by almost 50%. In
2008-2009 the company is launching two pioneering large-scale
screening platforms developed in close collaboration with leaders in
the pharmaceutical industry.
Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT
System enables high throughput RNAi screening and the Dynaflow(R)HT
System greatly advances ion channel drug discovery.